Sunday, October 4, 2026

EUR/USD Bearish Momentum: 0.54% Down Since The Last Session

ViaNews Editorial Team

January 8, 2021

EUR/USD Bearish Momentum: 0.54% Down Since The Last Session

EUR/USD is currently on bearish momentum. At 13:25 EST EST on Friday, 8 January, EUR/USD is at $1.2210, 0.54% down since the last session's close.

EUR/USD Range

EUR/USD is 0.302% down from its last session low of $1.2247 and 1.102% down from its last session high of $1.2346.

Over the last three sessions, EUR/USD's higher value was $1.2350 and the lower value was $1.2247.

Over the last seven sessions, EUR/USD's higher value was $1.2350 and the lower value was $1.2135.

Over the last month, EUR/USD's higher value was $1.2350 and the lower value was $1.2080.

EUR/USD's yearly highs and lows, it's 14.594% up from its 52-week low and 1.134% down from its 52-week high.

Volatility

EUR/USD's last day, last week, and last month's average volatility was 0.3300%, 0.0640%, and 0.0895%, respectively.

EUR/USD's last day, last week, and last month's high and low average amplitude percentage was 0.8100%, 0.7360%, and 0.5733%, respectively.

Last news about EUR/USD

Eur/usd, eur/jpy rates eyeing euro-area inflation and PMI figures. According to DailyFX on Monday, 4 January, "We typically take a contrarian view to crowd sentiment, and the fact traders are net-short suggests EUR/USD prices may continue to rise.", "Recent changes in sentiment warn that the current EUR/USD price trend may soon reverse lower despite the fact traders remain net-short."

According to DailyFX on Tuesday, 5 January, "Given dynamics in other major pairings such as EUR/USD or AUD/USD, GBP/USD may be one of the more attractive candidates to work with in scenarios of extended USD-strength."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com